A subscription to JoVE is required to view this content. Sign in or start your free trial.
The MDS diagnosis is difficult in the absence of morphological criteria or non-informative cytogenetics. MFC could help refine the MDS diagnostic process. To become useful for clinical practice, the MFC analysis must be based on parameters with sufficient specificity and sensitivity, and data should be reproducible between different operators.
A working group initiated within the French Cytometry Association (AFC) was developed in order to harmonize the application of multiparameter flow cytometry (MFC) for myeloid disease diagnosis in France. The protocol presented here was agreed-upon and applied between September 2013 and November 2015 in six French diagnostic laboratories (University Hospitals of Saint-Etienne, Grenoble, Clermont-Ferrand, Nice, and Lille and Institut Paoli-Calmettes in Marseille) and allowed the standardization of bone marrow sample preparation and data acquisition. Three maturation databases were developed for neutrophil, monocytic, and erythroid lineages with bone marrow from "healthy" donor individuals (individuals without any evidence of a hematopoietic disease). A robust method of analysis for each myeloid lineage should be applicable for routine diagnostic use. New cases can be analyzed in the same manner and compared against the usual databases. Thus, quantitative and qualitative phenotypic abnormalities can be identified and those above 2SD compared with data of normal bone marrow samples should be considered indicative of pathology. The major limitation is the higher variability between the data achieved using the monoclonal antibodies obtained with the methods based on hybridoma technologies and currently used in clinical diagnosis. Setting criteria for technical validation of the data acquired may help improve the utility of MFC for MDS diagnostics. The establishment of these criteria requires analysis against a database. The reduction of investigator subjectivity in data analysis is an important advantage of this method.
In the absence of phenotypic markers specific to the dysplastic changes occurring in myeloid cells during MDS initiation and progression, a new approach has been proposed in recent years based on the evaluation of the maturation pathways (altered expression of myeloid antigens during the production of mature myeloid cells) or of the abnormal distribution of different cell types within bone marrow (BM) cell compartments1,2.
This article presents a new method for standardized application of MFC in order to detect dysplastic changes in BM myeloid cell compartments related to myelodyspl....
The protocol listed below has been approved by the "Comité de Protection des Personnes" (Independant Ethics Committee) Sud-Est 1 from University Hospital of Saint-Etienne, France.
1. Cytometer Settings
NOTE: The cytometer settings were performed according to France Flow recommendations, in accordance with EuroFlow Procedure "EuroFlow Standard Operating Protocol (SOP) for Instrument Setup and Compensation (https://www.euroflow.org/usr/pub/protocols.php.......
The 54 BM samples harvested in K-EDTA anticoagulant were included in the study. The MFC data were analyzed in the absence of any information about the patients. Retrospective study showed that the BM samples were from 7 healthy donors (5 males and 2 females with a median age of 47.4 [35-48], 11 individuals with no evidence of a hematopoietic disease (8 males and 3 females with a median age of 57.9 [35-72]) and 36 cases with various pathological conditions: 1 case with anemia and low creat.......
The quality of BM aspirate could impact on the final results. The hemodilution of the BM aspirate could distort the distribution of cells in different stages of maturation due to the absence of progenitors or precursors cells. Probably employing a bulk lysing method may help in normalization of BM aspirates for hemodilution in flow cytometric analyses. In addition, the critical steps for the evaluation of BM myeloid dysplasia by flow-cytometry are the sample processing and staining, data acquisition, and interpretation
The antibodies used in this study were provided by BD Biosciences. The authors would like to thank their colleague, Dr. Pascale Flandrin-Gresta, from the Department of Molecular Biology, Hematology laboratory, University Hospital of Saint-Etienne, France, who provided expertise for interpretation of NGS data for the second MDS case. The authors are thankful for the clinician hematologists for their interest and involvement in this study and for the patients and healthy donors for their agreement to participate in this study. The authors would also like to thank the "Les Amis de Rémi" Foundation for financial support for publication.
....Name | Company | Catalog Number | Comments |
BD FACSCanto II flow-cytometer | BD Biosciences, CA, USA | SN: V33896301336 | 3-laser, 4-2-2 configuration, Filters and mirrors details: https://www.bdbiosciences.com/documents/BD_FACSCanto_II_FilterGuide.pdf |
Awel C48-R Centrifuge | AWEL Industries, FR | SN: 910120016; Model No: 320002001 | low speed centrifuges; capacity 60 FACS tubes |
Pipetts of 10µl and 200µl | |||
Pasteur pipettes | |||
15 mL Falcon tubes | |||
polypropylene tube for FACS | |||
Mouse Anti-Human HLA-DR | BD Biosciences, CA, USA | 655874 | clone L243 Mouse BALB/c IgG2a, κ Fluorochrome Horizon V450 (Ex max 404 nm/ Em max 448 nm) |
Mouse Anti-Human CD45 | BD Biosciences, CA, USA | 560777 | clone HI30 Mouse IgG1, κ Fluorochrome Horizon V500 (Ex max 415 nm/ Em max 500 nm) |
Mouse Anti-Human CD16 | BD Biosciences, CA, USA | 656146 | clone CLB/fcGran1 Mouse BALB/c IgG2a, κ Fluorochrome FITC (Ex max 494 nm/ Em max 520 nm) |
Mouse Anti-Human CD13 | BD Biosciences, CA, USA | 347406 | clone L138 Mouse BALB/c X C57BL/6 IgG1, κ Fluorochrome PE (Ex max 496 nm/ Em max 578 nm) |
Mouse Anti-Human CD34 | BD Biosciences, CA, USA | 347222 | clone 8G12 Mouse BALB/c IgG1, κ Fluorochrome PerCP-Cy5.5 (Ex max 482 nm/ Em max 678 nm) |
Mouse Anti-Human CD117 | BD Biosciences, CA, USA | 339217 | clone 104D2 Mouse BALB/c IgG1 Fluorochrome PE-Cy7 (Ex max 496 nm/ Em max 785 nm) |
Mouse Anti-Human CD11b | BD Biosciences, CA, USA | 333143 | clone D12 Mouse BALB/c IgG2a, κ D12, Fluorochrome APC (Ex max 650 nm/ Em max 660nm |
Mouse Anti-Human CD10 | BD Biosciences, CA, USA | 646783 | clone HI10A Mouse BALB/c IgG1, κ Fluorochrome APC-H7 (Ex max 496 nm/ Em max 785nm) |
Mouse Anti-Human CD35 | BD Biosciences, CA, USA | 555452 | clone E11 Mouse IgG1, κ Fluorochrome FITC (Ex max 494 nm/ Em max 520 nm) |
Mouse Anti-Human CD64 | BD Biosciences, CA, USA | 644385 | clone 10.1 Mouse BALB/c IgG1, κ Fluorochrome PE (Ex max 496 nm/ Em max 578 nm) |
Mouse Anti-Human CD300e | Immunostep | IREM2A-T100 | clone UP-H2 Mouse BALB/c IgG1, k Fluorochrome APC (Ex max 496 nm/ Em max 578 nm) |
Mouse Anti-Human CD14 | BD Biosciences, CA, USA | 641394 | clone MoP9 Mouse BALB/c IgG2b, κ Fluorochrome APC-H7 (Ex max 496 nm/ Em max 785nm) |
Mouse Anti-Human CD36 | BD Biosciences, CA, USA | 656151 | clone CLB-IVC7 Mouse IgG1, κ Fluorochrome FITC (Ex max 494 nm/ Em max 520 nm) |
Mouse Anti-Human CD105 | BD Biosciences, CA, USA | 560839 | clone 266 Mouse BALB/c IgG1, κ Fluorochrome PE (Ex max 496 nm/ Em max 578 nm) |
Mouse Anti-Human CD33 | 345800 | clone P67.6 Mouse BALB/c IgG1, κ Fluorochrome APC (Ex max 496 nm/ Em max 578 nm) | |
Mouse Anti-Human CD71 | BD Biosciences, CA, USA | 655408 | clone M-A712 Mouse BALB/c IgG2a, κ Fluorochrome APC-H7 (Ex max 496 nm/ Em max 785nm) |
Lysing Solution 10X Concentrate (IVD) | BD Biosciences, CA, USA | 349202 | |
FACSFlow Sheath Fluid | BD Biosciences, CA, USA | 342003 | |
FACSDiva CS&T IVD beads | BD Biosciences, CA, USA | 656046 | |
RAINBOW CALIBRATION PARTICLES, 8 PEAKS | Cytognos, Salamanca, Spain | SPH-RCP-30-5A | lots EAB01, EAC01, EAD05, EAE01, EAF01, EAG01, EAH01, EAI01, EAJ01, EAK01 |
Compensation Particles Multicolor CompBeads(CE/IVD) | BD Biosciences, CA, USA | ref. #51-90-9001229 + #51-90-9001291 | |
Diva software versions 6.1.2 and 6.1.3 | BD Biosciences, CA, USA | ||
Phosphate buffered saline tablets | R&D Systems, Minneapolis, USA | 5564 | |
Bovine serum albumin (BSA) | Sigma-Aldrich, France | A9647 | |
Sodium azide 99% | Sigma-Aldrich, France | 199931 | |
Infinicyt software version 1.8.0.e | Cytognos, Salamanca, Spain |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2025 MyJoVE Corporation. All rights reserved